Global Esomeprazole Market is segmented By Dosage Type(Vascular endothelial growth factor inhibitors (VEGF), Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, and BRAF or MEK Inhibitors), By Application(Immunotherapy, Targeted therapy, and Chemotherapy), By Distribution channels(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Esomeprazole Market Overview
The "Global Esomeprazole Market" is predicted to reach at a high CAGR during the forecast period (2024-2031).
Esomeprazole belongs to the proton pump inhibitors class of drugs that decreases the amount of acid produced in the stomach by obstructing H+/K+-ATPase in the stomach cells. It is a compound isomer omeprazole that is taken in the magnesium salt form. It is sold under the name of 'Nexium' and used to treat Erosive Esophagitis, Gastroesophageal reflux disease, Peptic ulcer, and Zollinger Ellison Syndrome route of administration of esomeprazole is oral or injected directly into the vein. Moreover, it has many side effects such as headache, constipation, dry mouth, abdominal pain, and some major side effects are Angioedema, Pneumonia and Clostridium infection. It is used for a safe pregnancy and also used post-pregnancy by females during breastfeeding. It is used in combination with antibiotics like amoxicillin and clarithromycin to prevent ulcers caused by Helicobacter pylori bacteria.
Source: DataM Intelligence Analysis (2020)
Esomeprazole Market Dynamics
The global esomeprazole market growth is driven by the growing cases of gastroesophageal reflux disease (GERD), and Increase in the adoption of drug delivery systems and successful launch of new products, Low treatment cost, readily availability and these drugs are sold without any prescription are the major factors.
Growing cases of gastroesophageal reflux disease (GERD), is expected to drive the global Esomeprazole market growth.
Gastroesophageal reflux disease is a chronic and pervasive disorder. GERD usually occurs when stomach acid frequently flows back into the tube connecting the mouth and stomach (esophagus). It is mostly found in the middle-aged and geriatric population. As per the report of “World Ageing Population, 2019”, approximately 702.9 million geriatric population was reported globally. Moreover, the combination of non-steroidal anti-inflammatory (NSAID) drugs and proton pump inhibitors decreases the risk of lower gastrointestinal bleeding. Hence, it is expected to rise the demand for esomeprazole market growth.
Minor & Major side effects of drugs is likely to hinder the market growth
Esomeprazole has many minor side effects of this drug like nausea, headaches, dry mouth, diarrhea, stomach pain and major side effects like kidney disease, dementia, difficulty in breathing, skin rashes, Angioedema, Pneumonia and Clostridium infection are the restricting factors of the esomeprazole market growth.
COVID-19 Impact Analysis on Esomeprazole Market
Due to the covid-19 pandemic outbreak, the market for Global Esomeprazole market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.
Esomeprazole Market Segment Analysis
Based on the dosage type, the global esomeprazole market is segmented into capsules, tablets and others
Capsule’s segment is expected to hold large share in the esomeprazole market. Esomeprazole capsule is coated with barrier polymer due to mortification of the drug in acidic conditions of the stomach and this is done by using the multiple-unit pellet system. Due to this esomeprazole tablets are also known as "multiple-unit pellet system" (MUPS). When the capsule is treated with aqueous solution, then water enters the capsule by osmosis and the contents get absorbed due to breakage of shell. For instance, in 2019, Zydus Cadila received a delayed-release US FDA (Food & Drug Administration) approval to manufacture and market esomeprazole magnesium delayed – release capsules. It is generally used to treat the symptoms of gastroesophageal reflux disease, to decrease the risk of stomach ulcers in some people taking pain medicines, to treat patients with a stomach infection (Helicobacter pylori).
Based on the application, the global esomeprazole market is segmented into gastroesophageal reflux disease, duodenal ulcers and others
Gastroesophageal reflux disease is a chronic and pervasive disorder. GERD usually occurs when stomach acid frequently flows back into the tube connecting the mouth and stomach (esophagus). It is mostly found in the middle-aged and geriatric population. As per the report of “World Ageing Population, 2019”, approximately 702.9 million geriatric population was reported globally. According to the National center for biotechnology information, the global GERD statistics, shows that the prevalence of GERD ranges from 18.1% to 27.8% in North America. For instance, On March 26, 2020, Cipla received a US FDA (Food & Drug Administration) to manufacture the generic version of AstraZeneca Pharmaceutical’s Nexium. It is used for treating GERD. Cipla is the first company to file for the 10mg strength.
Based on distribution channel, the hospital pharmacy are expected to dominate the global esomeprazole market during the forecast period
The hospital pharmacies held the largest share in the global esomeprazole market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Source: DataM Intelligence Analysis (2020)
Esomeprazole Market Geographical Share
North America region holds the largest market share global Esomeprazole market
North America holds a large share of the global esomeprazole market. Change in lifestyle and diet habits has been a major cause of issues related to stomach acid among people in the region. As per the report by Medscape (WebMD LLC.) In the U.S., peptic ulcer disease affects approximately 4.6 million people annually, with an estimated 10% of the U.S. population exhibiting evidence of a duodenal ulcer at some time. H pylori infection accounts for 90% of duodenal ulcers and 70% to 90% of gastric ulcers. Early symptoms and diagnosis help prevent the occurrence of the disease with the help of standard medication, such as Esomeprazole, which has also boosted the esomeprazole sodium market. In 2019, Nexium generated a revenue of $218 million from the U.S. alone.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Takeda's (Millennium Pharmaceuticals, Inc) study evaluates the effect of the proton pump inhibitor (PPI) esomeprazole on the single-dose PK of orally administered TAK-906 under Phase 1 trials.
Source: DataM Intelligence Analysis (2020)
Esomeprazole Market Competitive Landscape
The global esomeprazole market is highly competitive with some key competitors like Daiichi Sankyo, Astrazeneca PLC, Zydus Cadila Pharmaceuticals Inc., Takeda Pharmaceuticals, Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Dr. Reddy's Laboratories Inc., Torrent Pharma Inc., Amneal Pharmaceuticals LLC and Glenmark Pharmaceuticals. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market’s growth globally. For instance, Takeda- Phase 3 Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy with Oral TAK-438 20 mg Compared to Esomeprazole 20 mg Twice Daily in Subjects with Helicobacter Pylori Infection.
Astrazeneca PLC
Overview: AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It is perhaps best known for its involvement in developing the Oxford-Astrazeneca COVID-19 vaccine. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. They are more than 65,000 people in over 100 countries.
Product Portfolio: The company focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Product- Esomeprazole is sold under the brand name Nexium. It was first approved in February 2002 by the US FDA for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD) and also for erosive esophagitis.
Key developments:
Nexium - proton pump inhibitor is under investigating for stress ulcer prophylaxis of small molecule size which is approved in china waiting for approval in US, EU and Japan.
Why Purchase the Report?
- Visualize the composition of the global esomeprazole market segmentation by dosage type, by application, by distribution channel and region highlighting the key commercial assets and players.
- Identify commercial opportunities in esomeprazole market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of esomeprazole market- level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global esomeprazole market report would provide an access to an approx. market data 61 tables, 54 figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
